Company Profile
Epsilogen Ltd
10295520•Private Limited With Share Capital
Get Full Access
26/07/2016
9 years
6
21
72190
moderate risk
Company Overview
Registration, classification & business activity
Epsilogen Ltd (10295520) is a private limited with share capital incorporated on 26/07/2016 (9 years old) and registered in london, W69RH. The company operates under SIC code 72190 - other research and experimental development on natural sciences and engineering.
Epsilogen is a global leader in the development of immunoglobulin (ige) antibodies to treat cancer. ige has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.the company's lead programme targets th...
Financial Overview
£14.75M
£4.52M
£10.23M
£7.77M
Key Metrics
21
Employees
6
Directors
42
Shareholders
4
Patents
Board of Directors
Charges
4
Registered
2
Outstanding
0
Part Satisfied
2
Satisfied
Innovate Grants
This company received a grant of £1018197.99 for Development Of A Novel Immuno-Oncology Drug Targeting Solid Tumours. The project started on 01/04/2018 and ended on 30/06/2020.
This company received a grant of £523217.1 for Discovery Of Next Generation Her2 Antibodies For The Treatment Of Cancer. The project started on 01/01/2019 and ended on 30/11/2020.
+2 more grants available
Import / Export
Risk Assessment
moderate risk
International Score
Future Factor
emerging
Performance Rating